Share on StockTwits

Veracyte (NASDAQ:VCYT) CFO Shelly D. Guyer unloaded 1,250 shares of the stock on the open market in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $16.04, for a total transaction of $20,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday. They set an “overweight” rating and a $21.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $20.50.

Veracyte (NASDAQ:VCYT) traded up 3.38% on Monday, hitting $16.82. 211,405 shares of the company’s stock traded hands. Veracyte has a 1-year low of $10.88 and a 1-year high of $19.00. The stock has a 50-day moving average of $14.2 and a 200-day moving average of $14.93. The company’s market cap is $356.1 million.

Veracyte (NASDAQ:VCYT) last announced its earnings results on Thursday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter last year, the company posted ($9.04) earnings per share. Veracyte’s revenue was up 70.5% compared to the same quarter last year. On average, analysts predict that Veracyte will post $-1.31 earnings per share for the current fiscal year.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.